Breaking Barriers in Heart Failure: A New Role for Finerenone

      Major Milestone in Cardiovascular Therapy

      The U.S. Food and Drug Administration (FDA) has granted approval for finerenone (Kerendia™), a novel non-steroidal mineralocorticoid receptor antagonist, for a new indication - the treatment of heart failure (HF) in adults with a left ventricular ejection fraction (LVEF) ≥ 40%.

      Why This Matters

      Finerenone is the first drug in its class to demonstrate statistically significant and clinically meaningful cardiovascular benefits in patients with mildly reduced or preserved LVEF, a subgroup often underserved in heart failure management.

      Key takeaways:

• Targets the MR pathway, a key driver of inflammation and fibrosis in the heart.
• Reduces cardiovascular death, hospitalizations, and urgent heart failure visits.
• Backed by results from the Phase III FINEARTS-HF trial (part of the MOONRAKER program) - one of the largest trials ever conducted in HF with preserved LVEF.
• Receives FDA Priority Review status, expediting its approval due to significant clinical benefit.

      The Need Is Urgent

      Over 3.7 million people in the U.S. suffer from heart failure with LVEF ≥40%, contributing to over 500,000 hospitalizations annually. Until now, treatment options for this patient population have been limited, with persistently high rates of hospitalization and mortality.

      Dosage Details:

      Finerenone is available in 10 mg, 20 mg, and 40 mg oral tablets. The dose is usually tailored to the patient’s kidney function, potassium levels, and clinical condition.

      GEMS Insight

      Finerenone’s newly approved use could reshape clinical practice for heart failure by filling a critical gap in therapy for patients with preserved ejection fraction. With both renal and cardiovascular benefits, it may also offer dual protection in individuals with diabetes and comorbid HF—a promising frontier in integrated care.

Read More